This study provides valuable insights for potential therapeutic strategies that can enhance the anticancer efficacy of TCS by targeting HK2, suggesting that modulating aberrant glycolysis holds a promise to enhance the sensitivity of cancer cell to TCS-based therapeutic strategy. This evidence concerns the gene HK2 and cancer.